...
机译:患有耐药化疗的转移性非精原细胞性生殖细胞肿瘤患者的反复抢救手术成功成功缓解了2年
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Pathology Cancer Institute Japanese Foundation for Cancer Research Tokyo Japan;
Department of Surgery Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Surgery Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan;
Nonseminomatous germ cell tumor; Salvage surgery; Chemotherapy-resistant;
机译:在患有化疗耐药的转移性非精原细胞性生殖细胞肿瘤的患者中,反复进行挽救手术后成功缓解了2年。
机译:在患有化疗耐药的转移性非精原细胞瘤(校正)生殖细胞肿瘤的患者中,反复进行挽救手术后成功地长期(校正)缓解:Int J Clin Oncol 2007年的另一篇报道; 12:485-487。
机译:至理名言。回复:常规剂量疗法与大剂量化学疗法是男性转移性生殖细胞肿瘤患者的首例挽救疗法:来自大型国际数据库的证据。回复:转移性生殖细胞肿瘤患者的预后因素,以顺铂为基础的一线化疗治疗失败。
机译:初始救生患者患者治疗晚期胚芽细胞肿瘤:我们需要随机试验吗?
机译:Toll样受体(TLR)的表达和具有循环肿瘤细胞的转移性乳腺癌患者免疫系统细胞的功能。
机译:对于转移性生殖细胞肿瘤患者大剂量化疗是否比传统化疗更抢先治疗?
机译:原发性纵隔非精原性生殖细胞瘤患者的大剂量化疗和外周血干细胞移植的挽救疗法